SG11201907253VA - Proteins binding bcma, nkg2d and cd16 - Google Patents
Proteins binding bcma, nkg2d and cd16Info
- Publication number
- SG11201907253VA SG11201907253VA SG11201907253VA SG11201907253VA SG11201907253VA SG 11201907253V A SG11201907253V A SG 11201907253VA SG 11201907253V A SG11201907253V A SG 11201907253VA SG 11201907253V A SG11201907253V A SG 11201907253VA SG 11201907253V A SG11201907253V A SG 11201907253VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lebanon
- lucent
- pct
- drive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762457780P | 2017-02-10 | 2017-02-10 | |
PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907253VA true SG11201907253VA (en) | 2019-09-27 |
Family
ID=63107848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907253VA SG11201907253VA (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190375838A1 (de) |
EP (1) | EP3579876A4 (de) |
JP (2) | JP7257323B2 (de) |
KR (1) | KR20190115469A (de) |
CN (1) | CN110461361A (de) |
AU (1) | AU2018219348A1 (de) |
BR (1) | BR112019016424A2 (de) |
CA (1) | CA3054642A1 (de) |
IL (1) | IL268567A (de) |
MA (1) | MA47465A (de) |
MX (1) | MX2019009566A (de) |
SG (1) | SG11201907253VA (de) |
WO (1) | WO2018148566A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6698546B2 (ja) * | 2014-04-14 | 2020-05-27 | セレクティスCellectis | 癌免疫療法のためのbcma(cd269)特異的キメラ抗原受容体 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
AU2018220736A1 (en) | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
RU2020111554A (ru) * | 2017-08-23 | 2021-09-23 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
EP3833392A4 (de) * | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multispezifische bindende proteine zur bindung von cd33, nkg2d und cd16 sowie verfahren zur verwendung |
CA3136088A1 (en) * | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
CN116063550A (zh) * | 2020-09-02 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
EP4301402A1 (de) | 2021-03-03 | 2024-01-10 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispezifische antikörper zur verstärkung von zellvermittelten immunantworten |
WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1909832A4 (de) * | 2005-06-29 | 2010-01-13 | Univ Miami | Antikörper-immunzell-liganden-fusionsprotein für die krebstherapie |
KR101571027B1 (ko) * | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
PL2235064T3 (pl) * | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
CA2812739A1 (en) * | 2011-03-25 | 2012-10-04 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
AU2013268418B2 (en) * | 2012-05-30 | 2017-12-07 | Chugai Seiyaku Kabushiki Kaisha | Target-tissue-specific antigen-binding molecule |
BR112014032193A2 (pt) * | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico |
US9963513B2 (en) * | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
US20140323315A1 (en) * | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
KR102612313B1 (ko) * | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
WO2016134371A2 (en) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
JP6871232B2 (ja) * | 2015-04-06 | 2021-05-12 | サブドメイン リミテッド ライアビリティ カンパニー | 新規結合ドメイン含有ポリペプチドおよびその使用 |
CA3016563A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
AU2018219887A1 (en) * | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
EP3615068A1 (de) * | 2017-04-28 | 2020-03-04 | Novartis AG | Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor |
-
2018
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/de active Pending
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en active Pending
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en unknown
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Application Discontinuation
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt unknown
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3579876A4 (de) | 2020-11-18 |
CA3054642A1 (en) | 2018-08-16 |
KR20190115469A (ko) | 2019-10-11 |
CN110461361A (zh) | 2019-11-15 |
US20190375838A1 (en) | 2019-12-12 |
JP2020507328A (ja) | 2020-03-12 |
AU2018219348A1 (en) | 2019-08-29 |
JP2023029988A (ja) | 2023-03-07 |
MA47465A (fr) | 2019-12-18 |
MX2019009566A (es) | 2020-01-20 |
WO2018148566A1 (en) | 2018-08-16 |
EP3579876A1 (de) | 2019-12-18 |
RU2019127910A3 (de) | 2021-06-15 |
BR112019016424A2 (pt) | 2020-04-07 |
IL268567A (en) | 2019-09-26 |
RU2019127910A (ru) | 2021-03-10 |
JP7257323B2 (ja) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
SG11201907271PA (en) | Proteins binding psma, nkg2d and cd16 | |
SG11201907648XA (en) | Proteins binding gd2, nkg2d and cd16 | |
SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201907645PA (en) | Proteins binding cd123, nkg2d and cd16 | |
SG11201900501RA (en) | Cannabis composition | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof |